NCALD and ovarian serous adenocarcinoma: In the tissue array composed of 132 advanced high-grade serous ovarian cancer patient samples, immunohistochemistry also showed that the expression of NCALD and LAMA3 in chemoresistant patients was lower than that of chemosensitive patients (57.89% VS 39.58%, P = 0.048; 54.67% VS 42.55%, P = 0.041).